Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives (Q37382208)

20 August 2017

1 reference

title

Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives (English)

1 reference

20 August 2017

0 references

0 references

Zera Tellier

1 reference

20 August 2017

Marie-Hélène André

series ordinal

1 reference

20 August 2017

Benoît Polack

series ordinal

1 reference

20 August 2017

publication date

1 October 2009

1 reference

Clinical Reviews in Allergy & Immunology

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

125-134

1 reference

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12016-009-8115-4

Inhibitors in haemophilia A: current management and open issues

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12016-009-8115-4

Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy

21 January 2018

1 reference

12 December 2020

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

12 December 2020

Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography

1 reference

12 December 2020

HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII

1 reference

12 December 2020

Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor

1 reference

12 December 2020

A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine

1 reference

12 December 2020

Oral immune tolerance induction to factor VIII via breast milk, a possibility?

1 reference

12 December 2020

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development

1 reference

12 December 2020

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product

1 reference

12 December 2020

A role for the C2 domain of factor VIII in binding to von Willebrand factor

1 reference

12 December 2020

Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders

1 reference

12 December 2020

Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction

1 reference

12 December 2020

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

1 reference

12 December 2020

A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate

1 reference

12 December 2020

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate

1 reference

12 December 2020

Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A

1 reference

12 December 2020

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

1 reference

12 December 2020

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

1 reference

12 December 2020

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

1 reference

12 December 2020

Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.

1 reference

12 December 2020

Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution

1 reference

12 December 2020

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

1 reference

12 December 2020

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation

1 reference

12 December 2020

Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII an

1 reference

12 December 2020

Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate

1 reference

12 December 2020

The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability

1 reference

12 December 2020

The German Registry of immune tolerance treatment in hemophilia--1999 update.

1 reference

12 December 2020

Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

1 reference

12 December 2020

Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols

1 reference

12 December 2020

Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid

1 reference

12 December 2020

Letter: A more uniform measurement of factor VIII inhibitors

1 reference

12 December 2020

Identification of a F.VIII epitope recognized by a human hemophilic inhibitor

1 reference

12 December 2020

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

1 reference

12 December 2020

Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669.

1 reference

12 December 2020

Tolerance induction using the Malmö treatment model 1982-1995.

1 reference

12 December 2020

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

1 reference

12 December 2020

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.

1 reference

12 December 2020

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

1 reference

12 December 2020

Haemophilia A: mutation type determines risk of inhibitor formation

1 reference

12 December 2020

von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients

1 reference

12 December 2020

Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor

1 reference

12 December 2020

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1 reference

12 December 2020

Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate

1 reference

12 December 2020

VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study

1 reference

12 December 2020

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products

1 reference

12 December 2020

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

1 reference

12 December 2020

The North American Immune Tolerance Registry: practices, outcomes, outcome predictors

1 reference

12 December 2020

Management of factor VIII inhibitors

1 reference

12 December 2020

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

1 reference

12 December 2020

Some human inhibitor antibodies interfere with factor VIII binding to factor IX.

1 reference

12 December 2020

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

1 reference

12 December 2020

Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli

1 reference

12 December 2020

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

1 reference

12 December 2020

Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors

1 reference

12 December 2020

A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2

1 reference

12 December 2020

French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance

1 reference

12 December 2020

Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.

1 reference

12 December 2020

HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party

1 reference

12 December 2020

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

1 reference

12 December 2020

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery

1 reference

12 December 2020

Immune tolerance: critical issues of factor dose, purity and treatment complications

1 reference

12 December 2020

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

1 reference

12 December 2020

1 reference

12 December 2020

Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors

1 reference

12 December 2020

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

1 reference

12 December 2020

The international immune tolerance study: a multicenter prospective randomized trial in progress

1 reference

12 December 2020

Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

1 reference

12 December 2020

Role of von Willebrand factor in immune tolerance induction

1 reference

12 December 2020

Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs).

1 reference

12 December 2020

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

1 reference

12 December 2020

Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.

1 reference

12 December 2020

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

1 reference

12 December 2020

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

1 reference

12 December 2020

Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII

1 reference

12 December 2020

Systematic review of the management of patients with haemophilia A and inhibitors

1 reference

12 December 2020

Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients

1 reference

12 December 2020

Inhibition of human factor VIIIa by anti-A2 subunit antibodies

1 reference

12 December 2020

The management of inhibitors in haemophilia A: introduction and systematic review of current practice

1 reference

12 December 2020

The epidemiology of inhibitors in haemophilia A: a systematic review

1 reference

12 December 2020

Induction of immune tolerance in patients with hemophilia A and inhibitors

1 reference

12 December 2020

The use of the Port-A-Cath in children with haemophilia--a review

1 reference

12 December 2020

Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution

1 reference

12 December 2020

Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity

1 reference

12 December 2020

10.1007/S12016-009-8115-4

Identifiers

DOI

1 reference

20 August 2017

1 reference